RBC Capital Reiterates Outperform on ACADIA Pharmaceuticals, Maintains $29 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza has reiterated an Outperform rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) and maintained a price target of $29.
June 25, 2024 | 2:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital analyst Gregory Renza has reiterated an Outperform rating on ACADIA Pharmaceuticals and maintained a price target of $29.
The reiteration of an Outperform rating and a maintained price target of $29 by RBC Capital is a positive signal for investors, suggesting confidence in the company's future performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100